The Effects of a Third Generation Combined Oral Contraceptive Pill on the Classical Singing Voice

Journal of Voice

Volumn 21, Issue 6, 2007, Pages 754-761

  Lã, Filipa M B ^a   Ledger, William L ^a   Davidson, Jane W ^a   Howard, David M ^b   Jones, Georgina L ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Electrolaryngograph; Sexual hormones; Singing vocal performance; Third generation combined oral contraceptive pill

Indexed keywords

ANTIANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEX HORMONE; TESTOSTERONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MENSTRUAL CYCLE; RANDOMIZED CONTROLLED TRIAL; SINGING; STATISTICAL ANALYSIS; STUDENT; VOCAL CORD; VOICE; VOICE CHANGE;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GONADAL STEROID HORMONES; HUMANS; OCCUPATIONS; VOICE; VOICE QUALITY;

EID: 35848948613     PISSN: 08921997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvoice.2006.05.009     Document Type: Article

References (43)

1. Gelder L.V. Psychosomatic aspects of endocrine disorders of the voice. J Commun Disord 7 (1974) 257-262
2. Brodnitz F.S. Hormones and the human voice. Bull N Y Acad Med 47 (1971) 183-191
3. Dordain M. Etude statistique de l'influence des contraceptives hormonaux sur la voix. [in French]. Folia Phoniatri 24 (1972) 86-96
4. Wendler J., Siegert C., Schelhorn P., et al. The influence of Microgynon and Diane-35, two sub-fifty ovulation inhibitors, on voice function in women. Contraception 52 (1995) 343-348
5. Isenberg H., Brown W.S., and Rothman H.B. Effects of menstruation on the singing voice; Part II: Further developments in research. In: Laurence V. (Ed). Transcriptions of the Twelfth Symposium for the Care of the Professional Voice Part I (1983), The Voice Foundation, New York, NY 117-123
6. Damsté P.H. Voice change in adult women caused by virilizing agents. J Speech Hear Disord 32 (1967) 126-132
7. Beckford N.S., and Schaid D. Androgen stimulation and laryngeal development. Ann Otol Rhinol Laryngol 94 (1985) 634-640
8. Amir O., Kishon-Rabin L., and Muchnik C. The effect of oral contraceptives on voice: preliminary observations. J Voice 16 (2002) 267-273
9. Amir O., Biron-Shental T., Muchnick C., and Kishon-Rabin L. Do oral contraceptives improve vocal quality? Limited trial on low-dose formation. Obstet Gynaecol 4 (2003) 773-777
10. Amir O., and Biron-Shental T. The impact of hormonal fluctuation on female vocal folds. Curr Opin Otolaryngol Head Neck Surg 3 (2004) 180-184
11. Amir O., and Kishon-Rabin L. Association between birth control pills and voice quality. Laryngoscope 114 (2004) 1021-1026
12. Pocock S.T. Clinical Trials: A Practical Approach (1983), John Wiley & Sons, Singapore
13. Howard D.M. The human singing voice. Proc R Inst Great Britain 70 (1999) 113-134
14. Sundberg J. The Science of the Singing Voice (1987), Northern Illinois University Press, Dekalb, IL
15. Titze I.R. Principles of Voice Production. 2nd ed (2000), National Center for Voice and Speech, Iowa City, IA
16. Lin K.C., and Sun M.J. Relationship between sex hormone-binding glubulin and pregnancy outcome in women undergoing controlled ovarian hyperstimulation for assisted reproduction. Endocr J 52 (2005) 407-412
17. Howard D.M. Variation of electrolaryngographically derived closed quotient for trained and untrained adult female singers. J Voice 9 (1995) 163-172
18. Scherer R.C. Laryngeal function during phonation. In: Rubin J.S., Sataloff R.T., Korovin G.S., and Gould W.J. (Eds). Diagnosis and Treatment of Voice Disorders (1995), IGAKU-SHOIN, New York, NY 86-104
19. Hirano M. Clinical examination of voice. In: Harnold G.E., Winckel F., and Wyke B.D. (Eds). Disorders of Human Communication (1981), Springer/Verlag, Wien 1-98
20. Abberton E.R.M., Howard D.M., and Fourcin A.J. Laryngographic assessment of normal voice: a tutorial. Clin Linguist Phon 3 (1989) 281-296
21. Fourcin A.J., and Abberton E.R.M. First applications of a new laryngograph. Med Biol Rev 21 (1971) 172-182
22. Fourcin A.J., and Abberton E. Laryngograph studies of vocal-fold vibration. Phonetica 34 (1977) 313-315
23. Fourcin A.J. Electrolaryngographic assessment of vocal folds function. J Phon 14 (1986) 435-442
24. Fourcin A., Abberton E., Miller D., and Howells D. Laryngograph: speech pattern element tools for therapy, training and assessment. Eur J Disord Commun 30 (1995) 101-115
25. Abitbol J., and Abitbol B. Voix et ménopause: crépuscle des divas. [in French]. Contraceptive Fertile Sexuality 26 (1998) 649-655
26. Abitbol J., Abitbol P., and Abitbol B. Sex hormones and the female voice. J Voice 13 (1999) 424-446
27. Abitbol J., and Abitbol P. Endocrine disorders of the larynx. In: Ferlito A. (Ed). Diseases of the Larynx (2000), ARNOLD, London 311-333
28. Abitbol J., Brux J., Millot G., Masson M.F., Mimoun O.L., Pau H., and Abitbol B. Does a hormonal vocal cord cycle exist in women? Study of vocal premenstrual syndrome in voice performers by videoscopy-glottography and citology on 38 women. J Voice 3 (1989) 157-162
29. Fourcin A, McGlashan J, Blowes R. 2002. Measuring voice in the clinic-laryngograph speech studio analysis. Presented at the 6th Voice Symposium of Australia. Available at: http://www.laryngograph.com/papers.htm. Accessed November 4, 2004.
30. Miller R. Training Soprano Voices (2000), Oxford University Press, New York, NY
31. Sataloff R.T., Emerich K.A., and Hoover C.A. Endocrine dysfunction. In: Sataloff R.T. (Ed). Professional Voice: The Science and Art of Clinical Care. 2nd ed. (1997), Singular Publishing Group, San Diego 291-297
32. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., and Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5 (2000) 124-134
33. Laver J., Hiller S., and Beck J.M. Acoustic waveform perturbations and voice disorders. J Voice 6 (1992) 115-126
34. Newman S.-R., Butler J., Hammond E., and Gray S.D. Preliminary report on hormone receptors in the human vocal fold. J Voice 14 (2000) 72-81
35. Abramson A.L., Steinberg B.M., Gould W.J., Bianco E., Kennedy R., and Stock R. Estrogen receptors in the human larynx: clinical study of the singing voice. In: Laurence V. (Ed). Transcripts of the Thirteenth Symposium: Care of the Professional Voice Part II (1984), The Voice Foundation, New York, NY 409-413
36. Perello J., and Comas J. Etude de la cytology exfoliative du larynx. [in French]. Acta-Rhino-Laryngologica Belgica 13 (1959) 194-198
37. Parsey K.S., and Pong A. An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progesterone. Contraception 61 (2000) 105-111
38. Boschitsch E., Skarabis H., Wuttke W., and Heithecker R. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 5 (2000) 34-40
39. Huber J., Foidart J.M., Wuttke W., et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 5 (2000) 25-34
40. Foidart J.M. The Contraceptive profile of a new oral contraceptive with antimeneralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 5 (2000) 25-33
41. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., and Heithecker R. Effects of a new oral contraceptive containing an antimeneralocorticoid progestegen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
42. Yasmin prescribing information. Available at: http://www.intekom.com/pharm/schering/yasmin.html. Accessed April 25, 2006.
43. Fourcin A.J. Electrolaryngographic assessment of phonatory function. J Phon 14 (1987) 435-442